Морфологія і прогностичне значення строми рака передміхурової залози.

Автор(и)

  • I. I. Yakovtsova Харьковская медицинская академия последипломного образования, Україна
  • P. V. Tkachenko Харьковская медицинская академия последипломного образования, Україна
  • O. V. Dolgaya Харьковская медицинская академия последипломного образования, Україна
  • I. V. Ivachno Харьковская медицинская академия последипломного образования, Україна

DOI:

https://doi.org/10.26641/1997-9665.2016.3.342-348

Ключові слова:

рак передміхурової залози, десмоплазія, реактивна строма, прогноз, імуногістохімія

Анотація

В прогресії рака передміхурової залози ключову роль відіграє стромальних компонент, значення якого для прогнозу захворювання досліджено недостатньо. Мета: визначення взаємозв'язку між морфологічними характеристиками строми і прогностичними критеріями рака передміхурової залози. Виявлено достовірно значуща залежність між низкою ознак, що визначає ракову строму як важливий критерій прогнозу захворювання.

Посилання

Fedorenko ZP, Michailovich YY, Goulak LO, Gorokh YL, Ryzhov AY, Koutsenko LB, authors; Kolesnik OO, editor: [Bulletin of national cancer registry of Ukraine №17: “Cancer in Ukraine, 2014-2015”]. Kyiv: National cancer institute of Ukraine; 2016. 83 p. Ukraine.

Zellweger T, Günther S, Zlobec I, Savic S, Sauter G, Moch H, Mattarelli G, Eichenberger T, Curschellas E, Rüfenacht H, Bachmann A, Gas-ser TC, Mihatsch MJ, Bubendorf L. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer. 2009 May 1;124(9):2116-23. doi: 10.1002/ijc.24174.

Crawford ED, Bennett CL, Andriole GL, Garnick MB, Petrylak DP. The utility of prostate-specific antigen in the management of advanced prostate cancer. BJU Int. 2013 Sep;112(5):548-60. doi: 10.1111/bju.12061.

Fisher G, Yang ZH, Kudahetti S, Møller H, Scardino P, Cuzick J, Berney DM; Transatlantic Prostate Group. Prognostic value of Ki-67 for pros-tate cancer death in a conservatively managed cohort Br J Cancer. 2013 Feb 5;108(2):271-7. doi: 10.1038/bjc.2012.598.

De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol. 2003 Jul;200(4):429-47.

Taylor RA, Risbridger GP. Prostatic tumor stroma: a key player in cancer progression. Curr Cancer Drug Targets. 2008 Sep;8(6):490-7.

Yanagisawa N, Li R, Rowley D, Liu H, Kadmon D, Miles BJ, Wheeler TM, Ayala GE. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol. 2007 Nov;38(11):1611-20.

Tomas D, Spajić B, Milosević M, Demirović A, Marusić Z, Kruslin B. Intensity of stromal changes predicts biochemical recurrence-free survival in prostatic carcinoma. Scand J Urol Nephrol. 2010 Nov;44(5):284-90. doi: 10.3109/00365599.2010.485578.

Silva MM Jr, Matheus WE, Garcia PV, Stopiglia RM, Billis A, Ferreira U, Fávaro WJ. Characterization of reactive stroma in prostate can-cer: involvement of growth factors, metalloprotein-ase matrix, sexual hormones receptors and prostatic stem cells. Int Braz J Urol. 2015 Sep-Oct;41(5):849-58. doi: 10.1590/S1677-5538.IBJU.2014.0355.

European Association of Urology. Guide-lines on prostate cancer, 2015. Available from: https://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdf

Billis A, Meirelles L, Freitas LL, Polidoro AS, Fernandes HA, Padilha MM, Magna LA, Reis LO, Ferreira U. Adenocarcinoma on needle prostatic biopsies: does reactive stroma predicts biochemical recurrence in patients following radical prostatectomy? Int Braz J Urol. 2013 May-Jun;39(3):320-7. doi: 10.1590/S1677-5538.IBJU.2013.03.04.

Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, Wheeler M, Spitler J, Rowley DR. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res. 2003 Oct 15;9(13):4792-801.

Wu JP, Huang WB, Zhou H, Xu LW, Zhao JH, Zhu JG, Su JH, Sun HB. Intensity of stro-mal changes is associated with tumor relapse in clin-ically advanced prostate cancer after castration therapy. Asian J Androl. 2014 Sep-Oct;16(5):710-4. doi: 10.4103/1008-682X.129131.

Krušlin B, Ulamec M, Tomas D. Prostate cancer stroma: an important factor in cancer growth and progression. Bosn J Basic Med Sci. 2015 May 13;15(2):1-8. doi: 10.17305/bjbms.2015.449.

Placencio VR, Sharif-Afshar AR, Li X, Huang H, Uwamariya C, Neilson EG, Shen MM, Matusik RJ, Hayward SW, Bhowmick NA. Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. Cancer Res. 2008 Jun 15;68(12):4709-18. doi: 10.1158/0008-5472.CAN-07-6289.

Wikström P, Marusic J, Stattin P, Bergh A. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate. 2009 Jun 1;69(8):799-809. doi: 10.1002/pros.20927.

Singh M, Jha R, Melamed J, Shapiro E, Hayward SW, Lee P. Stromal androgen receptor in prostate development and cancer. Am J Pathol. 2014 Oct;184(10):2598-607. doi: 10.1016/j.ajpath.2014.06.022.

Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002 Sep;8(9):2912-23.

Dong Z, Nemeth JA, Cher ML, Palmer KC, Bright RC, Fridman R. Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 (timp-1) and timp-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer. 2001; 93:507-15.

Szarvas T, von Dorp F, Ergun S, Rubben H. Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. Nat Rev Urol. 2011 May;8(5):241-54. doi: 10.1038/nrurol.2011.44.

Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12493-8. doi: 10.1073/pnas.0601807103.

Folgueras AR, Pendas AM, Sanchez LM, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004; 48: 411–24.

##submission.downloads##

Номер

Розділ

Статті